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Abstract 
Dopamine (DA) is an endogenous neurotransmitter acting in the central nervous 
system. DA plays a key role in many vital brain functions such as behavior, cognition, 
motor activity, learning, and reward. Dopamine receptors belong to the rhodopsin like 
family of G-protein coupled receptors (GPCRs). There are five subtypes of DA 
receptors (D1-D5), which are further divided into two main families based on 
sequence similarities and their coupling to intracellular signaling (D1- and D2-like 
receptors). Dopamine agonists mimic the effects of the natural neurotransmitter and it 
has been found that selective dopamine D2 or D1 and mixed D1/D2 agonists are useful 
in the treatment of Parkinson disease. As D2 (but not D1) agonists have shown 
undesirable dyskinetic effects it is of highest interest to understand the reasons behind 
D1/D2 agonist selectivity. 
This thesis is focused on the identification of structural features that determine the 
selectivity of D1 and D2 receptor agonists for their respective receptors. Selective 
pharmacophore models were developed for both receptors. The models were built by 
using projected pharmacophoric features that represent the main agonist interaction 
sites in the receptor, and excluded volumes where no heavy atoms are permitted. The 
sets of D1 and D2 ligands used for modeling were carefully selected from published 
sources and consist of structurally diverse, conformationally rigid full agonists as 
active ligands together with structurally related inactives.  
3D receptor models in their agonist bound state were also generated for dopamine D1 
and D2, in order to get improved insight into agonist binding. The constructed D1 and 
D2 agonist pharmacophore models were superimposed into their corresponding 
receptor model. The arrangement of pharmacophoric features were in agreement with 
the position of the agonist key interacting amino acids in the binding site, with 
exception of one hydrogen bond accepting/donating feature in the D2 model and the 
positioning of the excluded volumes in both models. Both pharmacophore models 
were refined to better reflect the shape of the binding pocket and had similar 
pharmacophore hit rate when screening the test sets of dopamine ligands. Several key 
factors for D1/D2 agonist selectivity were identified.  
In addition, a semi-empirical method to model transmembrane proteins with focus on 
the ligand binding site has been developed. The method was evaluated by generating a 
β1-adrenergic receptor model which had an RMSD of 1.6 Å for all heavy atoms in the 
binding site relative the crystal structure. A D2 receptor model with an agonist present 
was constructed, but this model was unable to discriminate actives from inactives in a 
docking study.  
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